1-5 of 5
Ryo Nishikawa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Post-Hoc Analysis of the Final, Three-Year Follow-up Results of a Phase I/II Study on Tirabrutinib (ONO-4059) in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Noriko Fukuhara, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Hajime Yonezawa, Katsunori Asai, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa
Journal: Blood
Blood (2023) 142 (Supplement 1): 4472.
https://doi.org/10.1182/blood-2023-180438
Published: 2023
Journal Articles

Association between Microenvironment-Related Genes and Prognosis of Primary Central Nervous System Lymphoma

Keiichiro Hattori, Kenichi Makishima, Naoki Kurita, Yoshiaki Abe, Mamiko Sakata-Yanagimoto, Tatsuhiro Sakamoto, Sakurako Suma, Yasuhito Suehara, Ryota Matsuoka, Daisuke Matsubara, Motoo Nagane, Ryota Ishii, Ryo Nishikawa, Shota Tanaka, Akitake Mukasa, Yoshitaka Narita, Koichi Ichimura, Shingo Takano, Eiichi Ishikawa, Shigeru Chiba
Journal: Blood
Blood (2023) 142 (Supplement 1): 6081.
https://doi.org/10.1182/blood-2023-181517
Published: 2023
Journal Articles

Real-World Evidence for the Safety and Effectiveness of Tirabrutinib in 140 Japanese Patients with Recurrent or Refractory Primary Central Nervous System Lymphoma: Interim Report of Postmarketing Surveillance

Akira Kawasaki, Masaru Matsushita, Shingo Yoshida, Tanomu Matsukura, Koji Izutsu, Ryo Nishikawa
Journal: Blood
Blood (2022) 140 (Supplement 1): 6685–6686.
https://doi.org/10.1182/blood-2022-156472
Published: 2022
Journal Articles

Quality of Life and Karnofsky Performance Status in Patients with Relapse or Refractory Primary Central Nervous System Lymphoma during Phase I/II Study of Tirabrutinib

Yasuhito Terui, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yoshiki Arakawa, Hajime Yonezawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa
Journal: Blood
Blood (2021) 138 (Supplement 1): 4561.
https://doi.org/10.1182/blood-2021-146439
Published: 2021
Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1586.
https://doi.org/10.1182/blood-2019-123362
Published: 2019